查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1736680

全球关节痛注射剂市场：市场规模（按类型、应用、通路和地区划分）、未来预测

Global Joint Pain Injections Market Size By Type (Steroid Joint Injections, Hyaluronic Acid Injections), By Application (Shoulder & Elbow, Knee & Ankle), By Distribution Channel (Hospital Pharmacies, Online Pharmacies), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

关节痛注射剂的市场规模与预测

2024 年关节痛注射市场规模价值为 54.6 亿美元，预计到 2032 年将达到 99.6 亿美元，2026 年至 2032 年的复合年增长率为 7.80%。

关节疼痛注射市场涵盖全球用于缓解各种关节疾病相关疼痛和发炎的药物交易。这些注射通常含有皮质类固醇、透明质酸、富血小板血浆 (PRP) 和其他生物製药。关节疼痛注射为骨关节炎、类风湿性关节炎、肌腱炎、黏液囊炎和其他整形外科疾病等疾病提供了一种非侵入性或微创的手术干预替代方案。此细分市场面向广泛的人群，包括老龄化相关关节退化的老年人和遭受运动伤害的运动员。

推动全球关节痛注射市场发展的因素

关节痛注射剂的市场驱动力可能受到多种因素的影响。这些因素包括：

人口老化：随着全球人口老化，类风湿性关节炎和骨关节炎等关节相关疾病的发生率日益上升。预计这一人口趋势将推动注射等关节疼痛管理疗法的需求。

关节疾病增加：肥胖、久坐不动的生活方式、运动伤害和生活方式的改变导致关节疾病的发生率上升，因此需要注射等有效的缓解疼痛的技术。

偏好微创治疗：患者通常更倾向于微创治疗而非外科手术，因为微创治疗恢復时间较短、併发症较少、住院时间较短。关节疼痛注射是治疗疼痛和增强关节功能的手术替代方案。

技术发展：医疗技术的进步促成了比传统治疗方法更安全、更有效的新型注射疗法的开发，例如关节内粘稠补充疗法和富血小板血浆 (PRP) 注射。

提高意识和接受度：由于人们广泛了解早期疗育和有效疼痛管理技术的益处，患者和医疗保健专业人员越来越多地接受注射剂治疗关节疼痛。

发展医疗保健基础设施：发展医疗保健基础设施，特别是在新兴经济体，可以让人们更多地获得关节痛注射剂等专科治疗，从而增加市场潜力。

策略伙伴关係和协作：製药公司、医疗设备製造商和医疗保健提供者之间的联盟和协作正在促进新型注射关节痛药物和技术的开发、传播和采用。

监管支持：关节痛注射剂市场研发支出受到监管机构的优惠政策和倡议的刺激，这些政策和倡议支持采用创新治疗方法并加快新治疗方法的核准流程。

限制全球关节痛注射剂市场的因素

关节痛注射剂市场面临许多限制和挑战，其中包括：

疗效和长期效果有限：虽然关节疼痛注射可以缓解症状，但可能无法有效阻止病情长期发展，导致患者和医疗保健相关人员不满，并阻碍市场扩张。

昂贵的治疗：一些关节疼痛注射剂，尤其是较新的、更先进的注射剂，价格昂贵。经济方面的担忧可能会阻碍患者接受这些治疗，尤其是在医疗保健服务匮乏或自付费用较高的地区。

副作用与安全问题：虽然关节疼痛注射被认为是一种微创治疗方法，但它们也存在组织损伤、过敏反应、感染疾病。安全问题可能会影响医生和病人的意见，阻碍市场接受。

监管障碍：严格的监管和冗长的核准流程可能会延迟新型关节痛注射剂的上市，而且遵守不同地区不同的监管规范可能会很困难。

来自替代疗法的竞争：口服药物、物理治疗、手术等是关节疼痛注射必须面对的替代疗法。注射剂的市场占有率可能会受到替代疗法可用性的限制。

支付规则有限：支付规则不完善可能会阻碍患者获得关节疼痛注射剂，尤其是昂贵药物或新药。报销问题可能会影响治疗费用的可负担性以及医生注射的意愿，从而可能影响市场扩张。

市场分散化与整合：关节痛注射剂市场参与者众多，产品众多，导致市场分散化。激烈的竞争和主要参与者的整合尝试可能导致价格压力和利润率下降。

病患偏好与依从性问题：注射关节痛药物的使用可能受到病患偏好、治疗预期和信念的影响。患者对治疗方法的依从性和坚持性可能受到针头恐惧症、对侵扰感的感知以及不愿重复注射等因素的影响。

目录

第一章全球关节痛注射剂市场简介

  • 市场概览
  • 分析范围
  • 先决条件

第二章执行摘要

第三章 已验证的市场研究分析方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球关节痛注射市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

第五章全球关节痛注射剂市场（按类型）

  • 概述
  • 类固醇关节注射
  • 玻尿酸注射
  • 富血小板血浆（PRP）注射
  • 其他的

6. 全球关节痛注射剂市场（依应用）

  • 概述
  • 肩关节和肘关节
  • 膝关节和踝关节
  • 脊椎关节
  • 其他的

7. 全球关节痛注射剂市场（依通路）

  • 概述
  • 医院药房
  • 网路药局
  • 零售药局
  • 其他的

8. 全球关节痛注射剂市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他地区 (ROW)
    • 拉丁美洲
    • 中东和非洲

第九章全球关节痛注射剂市场的竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第十章 公司简介

  • Anika Therapeutics Inc
  • Pfizer Inc
  • Zimmer Biomet Holdings Inc
  • Flexion Therapeutics, Inc
  • SEIKAGAKU CORPORATION
  • Allergan Plc
  • Chugai Pharmaceutical Co. Ltd.
  • Bioventus LLC
  • Ferring BV
  • Sanofi SA

第十一章 附录

  • 相关分析
简介目录
Product Code: 39924

Joint Pain Injections Market Size And Forecast

Joint Pain Injections Market size was valued at USD 5.46 Billion in 2024 and is projected to reach USD 9.96 Billion by 2032, growing at a CAGR of 7.80% from 2026 to 2032.

The Joint Pain Injections Market encompasses the global trade in pharmaceutical products designed to alleviate pain and inflammation associated with various joint disorders. These injections typically include corticosteroids, hyaluronic acid, platelet-rich plasma (PRP), and other biologic agents. Joint pain injections offer a non-invasive or minimally invasive alternative to surgical interventions for conditions such as osteoarthritis, rheumatoid arthritis, tendinitis, bursitis, and other orthopedic ailments. This market segment caters to a wide range of demographics, including the elderly population experiencing age-related joint degeneration and athletes suffering from sports-related injuries.

Global Joint Pain Injections Market Drivers

The market drivers for the Joint Pain Injections Market can be influenced by various factors. These may include:

Ageing Population: As the world's population ages, joint-related conditions including rheumatoid arthritis and osteoarthritis are becoming more common. It is anticipated that this demographic trend would fuel demand for joint pain management therapies, such as injections.

Growing Incidence of Joint illnesses: Obesity, sedentary lifestyles, sports injuries, and lifestyle modifications all contribute to the rising prevalence of joint illnesses, which calls for efficient pain relief techniques like injections.

Preference for Minimally Invasive Treatments: Because minimally invasive treatments have shorter recovery times, fewer problems, and shorter hospital stays, patients frequently favour them over surgical methods. An alternative to surgery for treating pain and enhancing joint function is joint pain injections.

Technological Developments: As a result of ongoing improvements in medical technology, novel injection therapies with better safety and efficacy profiles than conventional treatments have been developed. Examples of these therapies include viscosupplementation and platelet-rich plasma (PRP) injections.

Growing Awareness and Acceptance: Patients and medical professionals alike are becoming more receptive to joint pain injections as a result of growing knowledge about the advantages of early intervention and efficient pain management techniques.

Development of Healthcare Infrastructure: Access to specialised therapies, such as joint pain injections, has increased due to improvements in healthcare infrastructure, particularly in emerging nations. This has expanded the market potential.

Strategic Partnerships and Collaborations: The development, dissemination, and uptake of novel joint pain injection products and technologies are facilitated by partnerships and collaborations among pharmaceutical companies, makers of medical devices, and healthcare providers.

Regulatory Support: Research and development expenditures in the joint pain injections market are stimulated by favourable regulatory policies and initiatives that support the adoption of innovative medical treatments and by accelerated approval processes for novel therapies.

Global Joint Pain Injections Market Restraints

Several factors can act as restraints or challenges for the Joint Pain Injections Market. These may include:

Limited Effectiveness and Long-Term Results: Although joint pain injections relieve symptoms, it's possible that they won't be as effective in stopping the progression of the condition over the long run. Patients' and healthcare professionals' unhappiness may result from this, which could hinder market expansion.

Expensive Treatment: Several joint pain injections, particularly the more recent and sophisticated ones, can be costly. Patients may be discouraged from pursuing these treatments due to financial concerns, especially in areas with little access to healthcare or high out-of-pocket costs.

Adverse Effects and Safety Concerns: Although joint pain injections are considered minimally invasive procedures, there are still potential hazards linked with them, such as tissue damage, allergic reactions, and infection. Concerns about safety could sway the opinions of doctors and patients, which would hinder market acceptance.

Regulatory Obstacles: Tight regulations and lengthy approval procedures may cause a lag in the release of novel joint pain injection solutions. Manufacturers may also have difficulties in adhering to differing regulatory norms in various geographical areas.

Competition from Alternative Therapies: Oral drugs, physical therapy, and surgical procedures are some of the alternative treatments that joint pain injections must contend with. The market share of injections may be restricted by the availability of alternative treatment options, particularly if these choices are thought to be equally or more effective.

Limited payment rules: Patients' access to joint pain injections may be hampered by inadequate payment rules, especially for expensive or novel medicines. Issues with reimbursement may affect treatment affordability and physicians' willingness to give injections, which may have an effect on market expansion.

Market Fragmentation and Consolidation: There are many manufacturers and products in the joint pain injections market, which causes market fragmentation. Price pressure and narrowed profit margins may be the outcome of fierce rivalry and major firms' attempts to consolidate.

Patient Preference and Compliance Issues: The use of joint pain injections may be influenced by a patient's preferences, treatment expectations, and beliefs. Patient compliance and adherence to treatment regimens may be impacted by variables such needle phobia, the perception of being intrusive, and reluctance to get repeated injections.

Global Joint Pain Injections Market Segmentation Analysis

The Global Joint Pain Injections Market is segmented on the basis of Type, Application, Distribution Channel, And Geography.

Joint Pain Injections Market, By Type

  • Steroid Joint Injections
  • Hyaluronic Acid Injections
  • Platelet-Rich Plasma (PRP) Injections
  • Others

Based on Type, The market is bifurcated into Steroid Joint Injections, Hyaluronic Acid Injections, Platelet-Rich Plasma (PRP) Injections, and Others.

Joint Pain Injections Market, By Application

  • Shoulder & Elbow
  • Knee & Ankle
  • Spinal Joints
  • Others

Based on Application, The market is bifurcated into Shoulder & Elbow, Knee & Ankle, Spinal Joints, and Others.

Joint Pain Injections Market, By Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Others

Based on Distribution Channel, The market is bifurcated into Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Others.

Joint Pain Injections Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of Geography, The Global Joint Pain Injections Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America may dominate the market due to the high prevalence of musculoskeletal disorders that causes joint pains. Increasing awareness of Non-invasive orthopedic treatments, continuous innovation in implant technologies, and advanced healthcare facilities.

Key Players

The "Global Joint Pain Injections Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as Anika Therapeutics, Inc, Pfizer Inc, Zimmer Biomet Holdings Inc., Flexion Therapeutics Inc, SEIKAGAKU CORPORATION, Allergan Plc, Chugai Pharmaceutical Co., Ltd, Bioventus LLC, Ferring B.V, and Sanofi S.A.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • December 2019: Flexion Therapeutics Inc, announced the U.S. FDA approval of the Supplemental New Drug Application to update the product label of ZILRETTA and give more clear information about the product.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL JOINT PAIN INJECTIONS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL JOINT PAIN INJECTIONS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL JOINT PAIN INJECTIONS MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Steroid Joint Injections
  • 5.3 Hyaluronic Acid Injections
  • 5.4 Platelet-Rich Plasma (PRP) Injections
  • 5.5 Others

6 GLOBAL JOINT PAIN INJECTIONS MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Shoulder & Elbow
  • 6.3 Knee & Ankle
  • 6.4 Spinal Joints
  • 6.5 Others

7 GLOBAL JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL

  • 7.1 Overview
  • 7.2 Hospital Pharmacies
  • 7.3 Online Pharmacies
  • 7.4 Retail Pharmacies
  • 7.5 Others

8 GLOBAL JOINT PAIN INJECTIONS MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East & Africa

9 GLOBAL JOINT PAIN INJECTIONS MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Anika Therapeutics Inc
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Pfizer Inc
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Zimmer Biomet Holdings Inc
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Flexion Therapeutics, Inc
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 SEIKAGAKU CORPORATION
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Allergan Plc
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Chugai Pharmaceutical Co. Ltd.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Bioventus LLC
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Ferring B.V
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Sanofi S.A.
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 Appendix

  • 11.1 Related Research